Table 4. Summary statistics^* of Nilotinib pharmacokinetic parameter values at steady-state (Day 8 or 15).

	Cohort 1 n=15	Cohort 2 n=6	Cohort 3 n=6	Cohort 4 n=5	Cohort 5 n=12
Nilotinib dose	400 mg bid	200 mg qd	400 mg qd	400 mg bid	400 mg bid
Imatinib dose	0 mg	400 mg bid	400 mg bid	400 mg bid	400 mg qd
tmax, h	2.8 (0-9.8)	4.0 2.9-6.3)	6.4 (1.9-23.8)	2.1 (0-12.5)	0 (0-5.0)
Cmax, ng/mL	1644±828	655±277	1236±705	2160±756	2509±1266
Cavg, ng/mL	1172±587	438±150	863±472	1617±610	1642±701
AUC0-t, ng*h/mL	13636±6617	10474±3491	20498±11135	18717±8516	16760±9450
CL/F, L/h	35.6±16.7†	21.5±9.3†	25.6±13.8†	24.8±10.0†	19.1±6.1‡

^*Median (range) for t_max and mean±SD for other PK parameters.

^†CL/F was estimated as dose/AUC_0-t.

^‡n=3; CL/F was estimated as dose/AUC_τ.